AKT1 and hepatocellular carcinoma: Research has shown that MET activates signalling pathways, such as the PI3K/AKT and RAS/MAPK pathways, promoting the proliferation, survival, and migration of hepatocellular carcinoma cells, as well as influencing vascular endothelial cells to promote neointimal formation (Bussolino et al., 1992; Bladt et al., 1995; Huh et al., 2004).